Xiansheng Pharmaceutical (02096) repurchase increased: spending HK$17.37 million on the repurchase, sending a positive signal of long-term development

The Zhitong Finance App learned that on October 9, Xiansheng Pharmaceutical (02096) announced that it would spend HK$17.369.89 million to buy back 1.598 million shares. This is the company's fifth share repurchase since September. Such frequent and vigorous repurchase operations have sent a clear valuation signal: the company has firm confidence in its intrinsic value and medium- to long-term development prospects.

On the performance side, Xiansheng Pharmaceutical's innovative drug transformation results continue to be realized. In the first half of this year, the company achieved revenue of 4.588 billion yuan, an increase of 27.8%; revenue from the innovative drug business was 3,887 billion yuan, accounting for 84.9% of the total revenue ratio, an increase of 34.1% over the previous year.

Recently, the transformation of the company's innovation pipeline welcomed another positive trend. At the beginning of September, Xiansheng Zaiming, an innovative anti-tumor drug company under Xiansheng Pharmaceutical, announced that it had reached an exclusive global license with Roche for SIM0660, and obtained a down payment of 75 million US dollars, a milestone of 1.455 billion US dollars, and a tiered sales commission of up to double digits. Up to now, Xiansheng Pharmaceutical Group has completed 6 external licenses, and the total potential transaction amount exceeds 6.1 billion US dollars.